Christopher Yea - 20 Nov 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role: CHIEF DEVELOPMENT OFFICER
Signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol: KALV
Transactions as of: 20 Nov 2025
Net transactions value: +$376
Form type: 4
Filing time: 21 Nov 2025, 16:07:51 UTC
Previous filing: 19 Nov 2025
Next filing: 26 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Yea Christopher	CHIEF DEVELOPMENT OFFICER	C/O KALVISTA PHARMACEUTICALS, INC, 200 CROSSING BOULEVARD, FRAMINGHAM	/s/ Benjamin L. Palleiko, Attorney-in-Fact	21 Nov 2025	0001691102

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KALV	Common Stock	Options Exercise	$376	+87,390	+65%	$0.004300	220,964	20 Nov 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KALV	Employee Stock Option (Right to Buy)	Options Exercise	$0	-87,390	-100%	$0.000000	0	20 Nov 2025	Common Stock	87,390	$0.004300	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option is 100% vested and exercised.